{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:51Z","timestamp":1788984831625,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sun pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01843-6","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:28:44Z","timestamp":1785432524000},"page":"4575-4584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world Tildrakizumab Effectiveness and Drug Survival: A Cohort Study in the PPD CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"16","author":[{"given":"Jerry","family":"Bagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Beeghly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"10281","key":"1843_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CE Griffiths","year":"2021","unstructured":"Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis Lancet. 2021;397(10281):1301\u201315.","journal-title":"Psoriasis Lancet"},{"key":"1843_CR2","unstructured":"World Health Organization. Global report on psoriasis. 2016. https:\/\/www.who.int\/publications\/i\/item\/9789241565189. Accessed 24 Oct 2025"},{"issue":"6","key":"1843_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1843_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Thaci","year":"2021","unstructured":"Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1843_CR5","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate to severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1843_CR6","first-page":"1","volume":"238","author":"KA Drerup","year":"2021","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021;238(4):1\u20135.","journal-title":"Dermatology"},{"issue":"4","key":"1843_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/ph16040526","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Lambiase S, Shumak RG, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16(4):526.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"1843_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s13555-024-01252-7","volume":"14","author":"M Burlando","year":"2024","unstructured":"Burlando M, Salvi I, Parodi A, Cozzani E. A 3-year experience with tildrakizumab treatment for patients with plaque psoriasis in clinical practice. Dermatol Ther (Heidelb). 2024;14(9):2645\u201352.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1843_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian Landscape Psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1843_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchella P, et al. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1843_CR11","first-page":"612","volume":"23","author":"J Heim","year":"2024","unstructured":"Heim J, Vasquez JG, Bhutani T, et al. Tildrakizumab real-world effectiveness and safety over 64 weeks in patients with moderate-to-severe plaque psoriasis. J Drugs Derm. 2024;23(8):612\u20138.","journal-title":"J Drugs Derm"},{"issue":"8","key":"1843_CR12","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s13555-025-01434-x","volume":"15","author":"VH Prajapati","year":"2025","unstructured":"Prajapati VH, Bellefontaine N, Gopalan D, et al. Tildrakizumab treatment patterns in adults with moderate-to-severe plaque psoriasis: a retrospective analysis from the Canadian Patient Support Program. Dermatol Ther (Heidelb). 2025;15(8):2047\u201359.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1843_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1843_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jdv.16187","volume":"34","author":"Y Poulin","year":"2020","unstructured":"Poulin Y, Ramon M, Rosoph L, et al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1500\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1843_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","volume":"90","author":"B Strober","year":"2024","unstructured":"Strober B, Ferris L, Callis Duffin K, et al. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;90(1):82\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1843_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s13555-022-00879-8","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Fitzgerald T, McLean RR, et al. Real-world effectiveness of 9\u201312 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(2):629\u201340.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1843_CR17","first-page":"762","volume":"24","author":"BE Strober","year":"2025","unstructured":"Strober BE, Janak JC, Fitzgerald T, et al. Two-year treatment persistence of guselkumab vs other biologics in plaque psoriasis patients. J Drugs Dermatol. 2025;24(8):762\u20138.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01843-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:37Z","timestamp":1788981697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01843-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jerry Bagel\n                      has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona LLC, Dermavant Sciences, Dermira, Lilly, Glenmark Pharmaceuticals Ltd, Janssen, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries Ltd, and UCB; is or has been a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Lilly, Janssen, Novartis, Sun Pharma, and UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen, and Novartis.\n                      Ranga Gogineni\n                      and\n                      Asif Shaikh\n                      are employees of Sun Pharmaceutical Industries, Inc.\n                      Taylor Blachley\n                      ,\n                      Thomas Eckmann\n                      , and\n                      Alicia Beeghly\n                      are employees and shareholders of Thermo Fisher Scientific.\n                      Mark G Lebwohl\n                      is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres Therapeutics, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall; AltruBio; Apogee; Arcutis Biotherapeutics; AstraZeneca; Atomwise; Avotres Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; Castle Biosciences; Celltrion; PPD\u2122 CorEvitas\u2122 Clinical Registries, Thermo Fisher Scientific; Dermavant Sciences; Dermsquared; Evommune; Facilitation of International Dermatology Education; Forte Biosciences; Galderma; Genentech; Incyte; LEO Pharma; Meiji Seika Pharma; Mindera; Pfizer; Sanofi-Regeneron; Seanergy; Strata; Takeda; Trevi; and Verrica. Mark G Lebwohl is an Editorial Board member of Dermatology and Therapy. Mark G Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review were obtained through a central institutional review board (IRB, Advarra, protocol no. Pro00051221). For academic investigative sites that did not receive a waiver to use the central IRB, approval was garnered from the respective governing IRBs and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All Registry participants provided written informed consent for participation and publication.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}